These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 22005952)
1. Hepoxilins in cancer and inflammation--use of hepoxilin antagonists. Pace-Asciak CR Cancer Metastasis Rev; 2011 Dec; 30(3-4):493-506. PubMed ID: 22005952 [TBL] [Abstract][Full Text] [Related]
2. Pathophysiology of the hepoxilins. Pace-Asciak CR Biochim Biophys Acta; 2015 Apr; 1851(4):383-96. PubMed ID: 25240838 [TBL] [Abstract][Full Text] [Related]
3. Hepoxilin analogs, potential new therapeutics in disease. Pace-Asciak CR; Li X; Qiao N; Reynaud D; Demin P; Abdelhaleem M Curr Pharm Des; 2006; 12(8):963-9. PubMed ID: 16533163 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Fang J; Seki T; Maeda H Adv Drug Deliv Rev; 2009 Apr; 61(4):290-302. PubMed ID: 19249331 [TBL] [Abstract][Full Text] [Related]
5. Hepoxilin analogs, PBT-3 and PBT-4, cause apoptosis of Gleevec-resistant K562 cells in vitro. Qiao N; Reynaud D; Abdelhaleem M; Pace-Asciak CR In Vivo; 2007; 21(2):267-71. PubMed ID: 17436575 [TBL] [Abstract][Full Text] [Related]
6. The hepoxilins and some analogues: a review of their biology. Pace-Asciak CR Br J Pharmacol; 2009 Oct; 158(4):972-81. PubMed ID: 19422397 [TBL] [Abstract][Full Text] [Related]
7. The hepoxilin analog, PBT-3, inhibits growth of K-562 CML solid tumours in vivo in nude mice. Li X; Qiao N; Reynaud D; Abdelhaleem M; Pace-Asciak CR In Vivo; 2005; 19(1):185-9. PubMed ID: 15796172 [TBL] [Abstract][Full Text] [Related]
8. Physiological and pathophysiological roles of hepoxilins and their analogs. Helal SA; Isse FA; Gerges SH; El-Kadi AOS Drug Metab Rev; 2023 Aug; 55(3):254-266. PubMed ID: 37264550 [TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic agents targeting the glucocorticoid receptor for inflammation and cancer. Sommer P; Ray DW Curr Opin Investig Drugs; 2008 Oct; 9(10):1070-7. PubMed ID: 18821468 [TBL] [Abstract][Full Text] [Related]
10. Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Calder PC Biochimie; 2009 Jun; 91(6):791-5. PubMed ID: 19455748 [TBL] [Abstract][Full Text] [Related]
11. [Exploring new therapeutic approaches to the treatment of inflammatory disorders--lipoxins]. Jarmakowska K; Kuna P Pol Merkur Lekarski; 2005 May; 18(107):578-80. PubMed ID: 16161960 [TBL] [Abstract][Full Text] [Related]
12. C5a receptor antagonists for the treatment of inflammation. Sumichika H Curr Opin Investig Drugs; 2004 May; 5(5):505-10. PubMed ID: 15202723 [TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Rubin P; Mollison KW Prostaglandins Other Lipid Mediat; 2007 May; 83(3):188-97. PubMed ID: 17481554 [TBL] [Abstract][Full Text] [Related]
14. The hepoxilin analog PBT-3 induces apoptosis in BCR-ABL-positive K562 leukemia cells. Qiao N; Lam J; Reynaud D; Abdelhaleem M; Pace-Asciak CR Anticancer Res; 2003; 23(5A):3617-22. PubMed ID: 14666657 [TBL] [Abstract][Full Text] [Related]
15. Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation, cancer, and metastasis. Das UN Cancer Metastasis Rev; 2011 Dec; 30(3-4):311-24. PubMed ID: 22005953 [TBL] [Abstract][Full Text] [Related]
16. Eicosanoid pathway in colorectal cancer: Recent updates. Tuncer S; Banerjee S World J Gastroenterol; 2015 Nov; 21(41):11748-66. PubMed ID: 26557000 [TBL] [Abstract][Full Text] [Related]
17. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. Coimbra M; Banciu M; Fens MH; de Smet L; Cabaj M; Metselaar JM; Storm G; Schiffelers RM J Control Release; 2010 Dec; 148(3):303-10. PubMed ID: 20869410 [TBL] [Abstract][Full Text] [Related]